Advanced glycation end products suppress osteoblastic differentiation of stromal cells by activating endoplasmic reticulum stress
- 30 August 2013
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 438 (3) , 463-467
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Advanced Glycation End Products (AGEs), but not High Glucose, Inhibit the Osteoblastic Differentiation of Mouse Stromal ST2 Cells Through the Suppression of Osterix Expression, and Inhibit Cell Growth and Increasing Cell ApoptosisCalcified Tissue International, 2012
- Diabetic Patients Have an Increased Risk of Vertebral Fractures Independent of BMD or Diabetic ComplicationsJournal of Bone and Mineral Research, 2009
- The Combination of High Glucose and Advanced Glycation End-products (AGEs) Inhibits the Mineralization of Osteoblastic MC3T3-E1 Cells through Glucose-induced Increase in the Receptor for AGEsHormone and Metabolic Research, 2007
- Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysisOsteoporosis International, 2006
- The Pathobiology of Diabetic ComplicationsDiabetes, 2005
- Diabetes and advanced glycation endproductsJournal of Internal Medicine, 2002
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- Advanced glycation end-products: a reviewDiabetologia, 2001
- Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinaseNature, 1999
- Protein folding in the cellNature, 1992